Comparing the efficacy of topical hydroquinone 2% versus intradermal tranexamic acid microinjections in treating melasma: a split-face controlled trial

Abstract Introduction: Melasma is a benign, acquired and chronic hypermelanosis. Topical hydroquinone (HQ) is a conventional choice to treat melasma. Tranexamic acid (TA) is a relatively new brightening agent that interferes with keratinocyte–melanocyte interactions. The aim of the present study was to compare the efficacy and safety of TA intradermal injections with HQ in treating melasma. Materials and methods: In this split-face controlled trial, 37 patients were randomized to receive three monthly sessions of TA intradermal injections either on the right or the left side of their face and topical HQ once a night for three months on the other side. Melanin and erythema were measured for each side of the face at the baseline and at the end of each month. Results: A reduction in melanin value was observed for TA and HQ separately (p value <.001). Monthly TA injection was better than daily HQ in reducing the melanin value during the first four weeks (p value =.013); but after 20 weeks, the overall changes was not different between the two groups (p value =.17). Conclusion: Monthly TA intradermal injections can be an effective treatment for melasma. Further studies are required to support our results.

[1]  M. Timalsina,et al.  Oral tranexamic acid for the treatment of melasma , 2018, Clincal and Experimental Dermatology.

[2]  S. Chua,et al.  Oral tranexamic acid lightens refractory melasma , 2017, The Australasian journal of dermatology.

[3]  Hei Sung Kim,et al.  Efficacy and Safety of Tranexamic Acid in Melasma: A Meta-analysis and Systematic Review. , 2017, Acta dermato-venereologica.

[4]  A. Ehsani,et al.  Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies , 2017, Dermatologic therapy.

[5]  K. Nouri,et al.  Tranexamic Acid in the Treatment of Melasma: A Review of the Literature , 2017, American Journal of Clinical Dermatology.

[6]  Nashwa N Elfar,et al.  Efficacy of Intradermal Injection of Tranexamic Acid, Topical Silymarin and Glycolic Acid Peeling in Treatment of Melasma: A Comparative Study , 2015 .

[7]  G. Kadhe,et al.  Evidence-Based Treatment for Melasma: Expert Opinion and a Review , 2014, Dermatology and Therapy.

[8]  M. Goldman,et al.  A randomized, split‐face clinical trial of low‐fluence Q‐switched neodymium‐doped yttrium aluminum garnet (1,064 nm) laser versus low‐fluence Q‐switched alexandrite laser (755 nm) for the treatment of facial melasma , 2014, Lasers in surgery and medicine.

[9]  B. Kasraee,et al.  Discrimination between cutaneous pigmentation and erythema: Comparison of the skin colorimeters Dermacatch and Mexameter , 2014, Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging.

[10]  Mira Choi,et al.  Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd:YAG laser , 2013, The Journal of dermatological treatment.

[11]  J. Na,et al.  Effect of tranexamic acid on melasma: a clinical trial with histological evaluation , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[12]  L. Budamakuntla,et al.  A Randomised, Open-label, Comparative Study of Tranexamic Acid Microinjections and Tranexamic Acid with Microneedling in Patients with Melasma , 2013, Journal of cutaneous and aesthetic surgery.

[13]  J. H. Lee,et al.  Oral Tranexamic Acid Enhances the Efficacy of Low‐Fluence 1064‐Nm Quality‐Switched Neodymium‐Doped Yttrium Aluminum Garnet Laser Treatment for Melasma in Koreans: A Randomized, Prospective Trial , 2013, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[14]  E. Hui,et al.  Tranexamic acid: an important adjuvant in the treatment of melasma , 2013, Journal of cosmetic dermatology.

[15]  A. Aggarwal,et al.  Melasma: Treatment strategy , 2011, Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology.

[16]  Hee Young Kang,et al.  What should be considered in treatment of melasma. , 2010, Annals of dermatology.

[17]  J. Ortonne,et al.  Therapeutical approaches in melasma. , 2007, Dermatologic clinics.

[18]  K. Hassun,et al.  A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma , 2007, Journal of cosmetic dermatology.

[19]  Keyvan Nouri,et al.  The treatment of melasma: a review of clinical trials. , 2006, Journal of the American Academy of Dermatology.

[20]  M. Picardo,et al.  Treatment of melasma. , 2006, Journal of the American Academy of Dermatology.

[21]  Mi-Yeon Kim,et al.  Localized Intradermal Microinjection of Tranexamic Acid for Treatment of Melasma in Asian Patients: A Preliminary Clinical Trial , 2006, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[22]  G. Costin,et al.  What is the mechanism for melasma that so commonly accompanies human pregnancy? , 2006, IUBMB life.

[23]  Arthur Rook,et al.  Rook's Textbook of Dermatology , 2004 .

[24]  B. Rao,et al.  Melasma: A Review , 2004, Journal of cutaneous medicine and surgery.

[25]  E. Camera,et al.  Chemical and instrumental approaches to treat hyperpigmentation. , 2003, Pigment cell research.

[26]  T. McCaffrey,et al.  Macrophage and foam cell release of matrix-bound growth factors. Role of plasminogen activation. , 1993, The Journal of biological chemistry.

[27]  H. Tagami,et al.  Leukotrienes and thromboxane B2 stimulate normal human melanocytes in vitro: possible inducers of postinflammatory pigmentation. , 1988, The Tohoku journal of experimental medicine.

[28]  H. Tagami,et al.  Stimulatory effect of prostaglandin E2 on the configuration of normal human melanocytes in vitro. , 1987, The Journal of investigative dermatology.

[29]  B. Bentley‐Phillips,et al.  Cutaneous reactions to topical application of hydroquinone. Results of a 6-year investigation. , 1975, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[30]  T. Fitzpatrick,et al.  Mechanism of depigmentation by hydroquinone. , 1974, The Journal of investigative dermatology.

[31]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[32]  P. Bahadoran,et al.  The Role of Topical Retinoids in the Treatment of Pigmentary Disorders , 2009, American journal of clinical dermatology.

[33]  H. Miot,et al.  [Physiopathology of melasma]. , 2009, Anais brasileiros de dermatologia.

[34]  G. Johnston,et al.  Recognition and Management of Common Ectoparasitic Diseases in Travelers , 2009, American journal of clinical dermatology.

[35]  Flávia Alvim Sant,et al.  Estudo de avaliação da efi cácia do ácido tranexâmico tópico e injetável no tratamento do melasma Study evaluating the effi cacy of topical and injected tranexamic acid in treatment of melasma , 2009 .

[36]  P. E. Grimes.  Melasma. Etiologic and therapeutic considerations. , 1995, Archives of dermatology.

[37]  V. Verallo-Rowell,et al.  Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. , 1989, Acta dermato-venereologica. Supplementum.

[38]  N. Higashi.  Treatment of Melasma with Oral Tranexamic Acid , 1988 .